COM MSG 10 SEP 90

File: 970815_sep96_decls23_0003.txt
Page: 0003
Total Pages: 5
Subject = COM MSG  10 SEP 90                                              

Parent Organization = MISC        

Unit = MISC        

Folder Title = MESSAGES-MEMORANDUMS-CHEMICAL PROTECTION SUBJECTS                                               

Document Number =          4

Box ID = BX005617








     AND SAFEGUARDING IT AGAINST LOSS. THE HAPP IS MORNRLLY SECURED IN
     THE SLEEVE OR BREAST POCKET OF THE CHEMICAL SUIT.
     4. TO BE MAXIMALLY EFFECTIVEs I PYRIDOSTIGNINE BROMIDE TABLET
     SHOULD BE TAKEN ORALLY EVERY 5 HOURS ON A CONTINUOUS BASIS PRIOR TO
     EXPOSURE TO A NERVE AGENT. (EXPOSURE) IN THIS SENSEI REARS ACTUAL
     POISONING OF THE SOLDIER, NOT 4UST OPERATIONS IN A CONTAMINATED
     ERVIROKKERT.) SOLDIERS SHOULD CONTINUE TRKIHG THE PYRIDOSTIGNINE
     UNTIL ALL 21 TABLETS IN THE BLISTER PACK HAVE BEEN USED OR UNTIL
     DIRECTED TO DISCONTINUE TAKING THE MEDICATION. IF IT IS TO BE
     CONTINUED PAST 7 DAYS; ANOTHER HAPP PACK MUST BE ISSUED. THIS
     REGINCH MAINTAINS AN EFFECTIVE BLOOD LEVEL OF THE MEDICATION. IF
     NOT TAKEN EVERY 6 HOURS@ THE BENEFICIAL EFFECT OF PYRIDOSTIGNINE AS
     A PRETREATMENT SIGNIFICANTLY DIMINISHES AFTER MORE IMAM A HOURS
     FROM THE LAST TABLET. THE USE OF PyRrDOSTIGHIME DOES NOT CHANGE
     THE ADMINISTRATION OF THE HARK 1.
     S. ALTHOUGH HO DETRIMENTAL EFFECTS ARE EXPECTED AT THE RECOMMENDED
     DOSAGEs DEPENDING ON THE LENGTH OF TIME ADKrHrSTEREDi AS WELL AS
     INDIVIDUAL PHYSIOLOGIC VARIATIONS* CERTAIN PERSONS MIGHT EXPERIENCE
     ADVERSE REACTIONS. THESE INCLUDE ABDOMINAL CRA?IP$T HAUSEAO




     PAGE U4 RMCGAR04329 UNCLAS
     DIARRHEA* SKIN RASH* MUSCLE VEAKNESSI CRAMPS AND TVITCHING@ OR
     DIMNESS OF VISION DOE TO PUPILLARY CONSTRICTION. IF ANY OF THE
     ABOVE SIGHS/SYMPTOMS OCCUR* THE SOLDIER SHOULD CONTACT UNIT MEDICAL
     PERSONNEL AS SOON AS POSSIBLE.
     64 WHEN THE ORDER TO TAKE Py7RroOgTlcmrmc HAS BEEN GIVER, IT Smouti)
     BE rhiEN AS DIRECTED #:YEN. rf- TFir. "PP LF-VF-L REQUIRES THE PitOTECTrv E'
     RASK BE *ORR-. *S- LONG Al THF@ F-*VrROUtIE.4r- rs coOrAnrxATED Olt IS
     ulKELY TO BECOME $Ot IT-'IT DV-SLAITBLE TO CONTINUE THE PRETREATMENT.
     MOVEVER* IF THE MISSION REQUIRES SOLDIERS TO REMAIN IN A
     CONTAMINATED ENVIRONMENT FOR EXTENDED PERIOO$4 COLLECTIVE
     PROTECTION OR REST AND RELIEF SHELTERS SHOULD BE PROVIDED SO THAT
     THEY CAN REMOVE THEIR PROTECTIVE MASK AND TAKE THE T49LETS# OR THEY
     SHOULD BE RELOCATED-TO AN URCOMTI%KINATED AREA VHEREVER POSSIALE.
     7. At TIMES A COMMANDER RAY HAVE TO MAKE A DECISION TO DEFER
     DRINISTRATZOH OF THE PYRROOSTIGNINE ON SCHEDULE. FOR EXAMPLE, IF
     THE SITUATION IS SUCH THAT TAKING THE TABLETS WOULD BE HAZARDOUS,
     SUCH AS VHEH IN A TOXIC CHEMICAL AEROSOL ENVIRONMENT OR IN A
     CONrAffrXATED AREA AT NIGHT WITHOUT LIGHTINGs THEM IT WOULD BE MORC
     APPROPRIATE TO DELAY TAKING THE MEDICATION FOR A FEW HOURS UNTIL
     rHE TABLETS CAM BE TAKEN IN A LESS HAZARDOUS ENVIRONMENT.     COMMAND.-




     PAGE a5 RKCGAN0432A UMCLAS
     GUIDELINES SHOULD BE 9EVELOPED TO HANDLE THE PARTICULAR SITUATION.
     &- IT IS THE RESPIONSIBILITY OF THE CORPS OR DIVISION COMMANDER TO
     DECIDE WHETHER TO BEGIN, CONTINUE* OR DISCONTINUE THE HAPP
     HEORCATION BASED ON THE THREAT. THE INTELLIGENCE OFFICER 09
     CHEMICAL OFFICER AND THE SURGEON ACT AS ADVISORS TO THE COMMANDER
     IN NAKINO HIS DECISION. AFTER THREE DAYS OF $ELF-ADOINISTRATION OF
     THE MEDICATION If THE SOLDIEte COMBAT CONDITIONS SUOULD BE
     REEVALUATED BY THE COMMANDER AND HIS STAFF FOR A DETERMINATION OF
     WHETHER TO CONTINUE THE MEDICATION OR HOT. HOUEVEto ORDERS TO
     CONTINUE 01 DISCONTINUE THE PRETREATMENT CAN AND SHOULD BE MADE AT
     ANY TIREA OEFENDtOre ON THE SITUATION. IF THE MEDICATION IS TO BE
                                  I